EQT to buy molecular testing firm Qiagen for $10.8 billion
EQT will acquire Qiagen for €9.6B ($10.78B), offering €46.50 ($52.22) per share, an 8.6% premium. Qiagen's shares rose 0.7% post-announcement. The deal, valued at $12.1B including debt, is expected to close in mid-2027. Qiagen's board approved the offer, citing it as the best path forward. The company suspended its 2026 outlook and reported Q3 net sales of $548M and adjusted EPS of $0.65.
How this was made
The 30-second read
Why it matters
The announcement provides a clear catalyst for Qiagen's stock, with a modest immediate price uptick and likely continued upside as the deal progresses toward a mid‑2027 close.
Market read
First‑report of a major M&A transaction that directly moves a US‑listed biotech stock, offering a concrete trading opportunity.
What to watch
Potential integration risks and the impact of Qiagen's pending full‑year outlook suspension on future earnings.
Background
EQT, a Sweden‑based private‑equity firm, is expanding its portfolio in molecular diagnostics by targeting Qiagen, a Dutch‑origin company listed in the US. The offer follows prior interest from other PE firms and a failed 2020 acquisition attempt by Thermo Fisher.
Ticker impact
Qiagen announced a definitive €9.6 billion buyout by EQT, offering €46.50 per share, a premium that caused its US‑listed shares to rise 0.7% in extended trading.
modest upside as the market incorporates the 8.6% premium and buy‑out certainty
Deal is newly disclosed, large scale, and already moved the share price; no competing bids are mentioned.
Market effects
The deal underscores private‑equity appetite for molecular‑testing firms, potentially prompting valuation reassessments in the biotech diagnostics sector.
European private‑equity activity may see heightened interest, but direct impact is limited to US‑listed Qiagen.
Large‑cap M&A of this size can influence global biotech M&A sentiment and comparable deal multiples.
Counterpoint
If the deal faces regulatory hurdles or financing delays, the premium could evaporate, leaving the stock vulnerable to a pull‑back.
Key entities
- private equity firmEQT
Acquirer offering €46.50 per share.
- public companyQiagen
Target of the €9.6 billion buyout, ticker QGEN.

